MERCK CO. DL-,01/ US58933Y1055 /
26/04/2024 17:47:34 | Chg. +1.600 | Volume | Bid22:00:01 | Ask22:00:01 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
122.600EUR | +1.32% | 0 Turnover: 0.000 |
-Bid Size: - | -Ask Size: - | 310.74 bill.EUR | - | - |
GlobeNewswire
06/03
IO Biotech Announces Acceptance of Abstract to be Presented at the 2024 American Association for Can...
GlobeNewswire
04/03
C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Ger...
GlobeNewswire
21/12/2023
Arch Biopartners Receives Approval from Ethics Committee in Turkey to Proceed with Phase II Cardiac ...
GlobeNewswire
19/12/2023
Unnatural Products, Inc. Announces $32 Million in Series A Funding Led by Merck Global Health Innova...
GlobeNewswire
14/12/2023
ITM Executes License Agreement to Obtain Worldwide Exclusive License for the Clinical Development an...
GlobeNewswire
12/12/2023
C4 Therapeutics Announces License and Research Collaboration with Merck to Discover and Develop Degr...
GlobeNewswire
05/12/2023
HiberCell, Inc. Announces Clinical Collaboration with Merck to Evaluate HC-7366, an Activator of ISR...
GlobeNewswire
04/12/2023
Nasdaq Grants Vaccinex Extension Until March 4, 2024 to Regain Compliance with Listing Rule
GlobeNewswire
13/11/2023
Vaccinex Reports Third Quarter 2023 Financial Results and Provides Corporate Update
GlobeNewswire
17/10/2023
ImmunOs Therapeutics Announces Clinical Trial Collaboration with Merck & Co., Inc., Rahway, NJ, USA